

Immunotag™ RelB Polyclonal Antibody

Antibody Specification	
Catalog No.	ITT4045
Product Description	Immunotag™ RelB Polyclonal Antibody
Size	50 µg, 100 µg
Conjugation	HRP, Biotin, FITC, Alexa Fluor® 350, Alexa Fluor® 405, Alexa Fluor® 488, Alexa Fluor® 555, Alexa Fluor® 594, Alexa Fluor® 647
IMPORTANT NOTE	This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return.
Target Protein	RelB
Clonality	Polyclonal
Storage/Stability	-20°C/1 year
Application	WB,ELISA
Recommended Dilution	Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.
Concentration	1 mg/ml
Reactive Species	Human,Mouse
Host Species	Rabbit
Immunogen	The antiserum was produced against synthesized peptide derived from human RelB. AA range:530-579
Specificity	RelB Polyclonal Antibody detects endogenous levels of RelB protein.
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen
Form	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Gene Name	RELB
Accession No.	Q01201 Q04863
Alternate Names	RELB; Transcription factor RelB; I-Rel

Antibody Specification

Description	caution:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B.,domain:Both N- and C-terminal domains are required for transcriptional activation.,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.,induction:By mitogens.,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.,similarity:Contains 1 RHD (Rel-like) domain.,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.,
Cell Pathway/ Category	MAPK_ERK_Growth,MAPK_G_Protein,
Protein Expression	Blood,T-cell,
Subcellular Localization	nucleus,nucleoplasm,cytoplasm,microtubule organizing center,cytosol,I-kappaB/NF-kappaB complex,

Antibody Specification

Protein Function	caution:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B.,domain:Both N- and C-terminal domains are required for transcriptional activation.,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.,induction:By mitogens.,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.,similarity:Contains 1 RHD (Rel-like) domain.,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.,
Usage	For Research Use Only! Not for diagnostic or therapeutic procedures.